15880-03-2

Basic information

• Product Name: 3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID
• Synonyms: Propionicacid, 3-(2,4-dimethylbenzoyl)- (6CI,8CI);3-(2,4-Dimethylbenzoyl)propionicacid;4-(2,4-Dimethylphenyl)-4-oxobutanoic acid;NSC 163163
• CAS NO: 15880-03-2
• Molecular Formula: C₁₂H₁₄O₃
• Molecular Weight: 206.2436
• Mol File: 15880-03-2.mol
• Article Data: 16

Chemical Properties

• Melting Point: 110～113℃
• Boiling Point: 389.6 °C at 760 mmHg
• Flash Point: 203.6 °C
• Appearance: /
• Density: 1.138 g/cm³
• Vapor Pressure: 9.1E-07mmHg at 25°C
• Refractive Index: 1.539
• PKA: 4.58±0.17(Predicted)
• CAS DataBase Reference: 3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID(15880-03-2)
• EPA Substance Registry System: 3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID(15880-03-2)

Safety Data

• Hazardous Substances Data: 15880-03-2(Hazardous Substances Data)

Usage

General Description

3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID is a chemical compound with the molecular formula C13H16O3. It is a derivative of benzoylpropionic acid and is commonly used as a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. It works by inhibiting the production of prostaglandins, which are responsible for causing pain and inflammation in the body. This chemical is often used in the treatment of conditions such as arthritis, menstrual cramps, and mild to moderate pain. It is important to use this chemical under the supervision of a healthcare professional, as it may have potential side effects and interactions with other medications.

InChI:InChI=1/C12H14O3/c1-8-3-4-10(9(2)7-8)11(13)5-6-12(14)15/h3-4,7H,5-6H2,1-2H3,(H,14,15)

Upstream product

• 543-20-4 succinoyl dichloride 
• 108-38-3 m-xylene 
• 108-30-5 succinic acid anhydride 

Downstream Products

• 13621-26-6 4-(2,4-dimethyl-phenyl)-butyric acid 
• 150074-87-6 1-(2,4-dimethylphenyl)-1,4-butanediol 
• 1476801-88-3 6-(2,4-dimethylphenyl)-2-(4-(4-hydroxyphenyl)thiazol-2-yl)-4,5-dihydropyridazin-3(2H)-one 
• 1476801-93-0 6-(2,4-dimethylphenyl)-2-(4-(4-methoxyphenyl)thiazol-2-yl)-4,5-dihydropyridazin-3(2H)-one 
• 1325209-97-9 (E)-3-[(2,6-dichloroquinolin-3-yl)methylene]-5-(2,4-dimethylphenyl)-furan-2(3H)-one 
• 1325209-98-0 (E)-3-[(2-chloro-6-methoxyquinolin-3-yl)methylene]-5-(2,4-dimethylphenyl)-furan-2(3H)-one 
• 1325209-96-8 (E)-3-[(2-chloro-6-methylquinolin-3-yl)methylene]-5-(2,4-dimethylphenyl)-furan-2(3H)-one 
• 1325209-95-7 (E)-3-[(2-chloroquinolin-3-yl)methylene]-5-(2,4-dimethylphenyl)-furan-2(3H)-one 
• 71823-08-0 6-(2,4-dimethylphenyl)-2-phenyl-4,5-dihydropyridazin-3(2H)-one 
• 64262-74-4 3-chloro-6-(2,4-dimethyl-phenyl)-pyridazine 
• 4869-37-8 6-(2,4-dimethyl-phenyl)-4,5-dihydro-2H-pyridazin-3-one 
• 1268133-87-4 3-(4'-tolyl)-6-(2',4'-dimethylphenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1268133-85-2 3-phenyl-6-(2',4'-dimethylphenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 64262-87-9 C₁₂H₁₄N₄ 

Relevant articles and documents

An efficient one-pot synthesis of pyridazinones and phthalazinones using HY-zeolite

Figure represented. The first one-pot synthesis of pyridazinones and phthalazinones from arenes, cyclic anhydrides, and ArNHNH2 in the presence of efficient recyclable heterogeneous catalyst, HY-zeolite, in high yield and short reaction time is reported.

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.